Strategic partnerships SpiroChem has a track record of collaborating with notable CROs and pharmaceutical players (Dalriada Drug Discovery, Arctoris, EUROAPI UK) and active expansion through acquisitions (Cyclenium Pharma) to broaden capabilities and geographic reach, signaling opportunities to pitch integrated discovery and early process R&D services alongside partner networks.

Expansion momentum With a Basel headquarters and a second R&D site in Montreal, plus recent collaboration announcements and a Nordic-style cross-border footprint, there is a clear appetite for regional expansion that can be leveraged to offer co-development projects and cluster-based engagements in Europe and North America.

Macrocyclic focus Strategic acquisition of Cyclenium Pharma expands macrocyclic therapeutic capabilities, presenting sales opportunities to clients designing complex macrocyclics or requiring specialized chemistry for challenging targets, along with cross-sell into existing medicinal chemistry and early process R&D services.

Integrated CRO-CDMO value SpiroChem positions itself as an integrated partner across discovery, hit validation, lead optimization, and early process R&D, enabling conversations about end-to-end outsourcing, regulatory milestone support, and seamless transition from discovery to scalable manufacturing with partner networks.

Market credibility A proven high success rate and strong customer/academic feedback, coupled with ongoing high-visibility partnerships, create a compelling case for targeting pharmaceutical companies seeking reliable CRO partners for speed, quality, and transparent collaboration in chemistry and related biology services.